Loading...
•
Dec 31, 2021
Beam Therapeutics Q4 2021 Earnings Report
Pipeline and business highlights were reported, 2022 milestones were planned, and fourth quarter and full year 2021 financial results were announced.
Key Takeaways
Beam Therapeutics reported a strong cash position of $1.2 billion, including a $300 million upfront payment from Pfizer, to support milestones across ex vivo and in vivo base editing programs. The company is advancing its sickle cell disease strategy with planned clinical trials for BEAM-101 and BEAM-102.
Executed a multi-target research collaboration with Pfizer, receiving a $300 million upfront payment.
Advanced ex vivo base editing programs for sickle cell disease.
Presented preclinical data on multiplex edited CAR T-cells for CD5-positive tumors.
Plans to enroll the first subject in the Phase 1/2 clinical trial of BEAM-101 for the treatment of SCD in the second half of 2022.
Beam Therapeutics
Beam Therapeutics
Forward Guidance
Beam Therapeutics anticipates several milestones in 2022, including IND submissions and clinical trial initiations for its ex vivo HSC and T cell programs, as well as advancing its in vivo LNP liver-targeting programs.
Positive Outlook
- Enroll the first subject in the Phase 1/2 clinical trial of BEAM-101 for the treatment of SCD in the second half of 2022
- Submit an investigational new drug (IND) application for BEAM-102 for the treatment of SCD in the second half of 2022
- Submit an IND application for BEAM-201 for the treatment of relapsed/refractory T cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma (T-ALL/TLL) in the second half of 2022
- Nominate a second CAR-T development candidate in 2022
- Initiate IND-enabling studies for BEAM-301
Challenges Ahead
- Ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned
- Ability to raise additional funding, which may not be available
- Ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates
- Preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials
- Product candidates may experience manufacturing or supply interruptions or failures